Abstract
Despite the fact that anti-TNF alpha antibodies are well-tolerated and highly effective in Crohns disease 25% to 40% of patients who initially benefited from the treatment are developing intolerable adverse events or are losing their response during maintenance therapy. The molecular mechanisms of loss of response are not fully understood, but clinicians face this clinical problem. The Aim of this paper is to review the clinical strategies to face loss of response to anti- TNF alpha antibodies in Crohns disease.
Current Drug Targets
Title: “How to Manage Loss of Response to Anti-TNF in Crohns Disease?”
Volume: 11 Issue: 2
Author(s): Walter Reinisch
Affiliation:
Abstract: Despite the fact that anti-TNF alpha antibodies are well-tolerated and highly effective in Crohns disease 25% to 40% of patients who initially benefited from the treatment are developing intolerable adverse events or are losing their response during maintenance therapy. The molecular mechanisms of loss of response are not fully understood, but clinicians face this clinical problem. The Aim of this paper is to review the clinical strategies to face loss of response to anti- TNF alpha antibodies in Crohns disease.
Export Options
About this article
Cite this article as:
Reinisch Walter, “How to Manage Loss of Response to Anti-TNF in Crohns Disease?”, Current Drug Targets 2010; 11 (2) . https://dx.doi.org/10.2174/138945010790309894
DOI https://dx.doi.org/10.2174/138945010790309894 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Second Generation of COX-2 Inhibitors: Clinical Pharmacological Point of View
Mini-Reviews in Medicinal Chemistry The Genetic Basis of Graves Disease
Current Genomics Aging and Systemic Lupus Erythematosus - Immunosenescence and Beyond
Current Aging Science Activities of Venom Proteins and Peptides with Possible Therapeutic Applications from Bees and WASPS
Protein & Peptide Letters Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective
Current Rheumatology Reviews Survey of Epstein Barr Virus (EBV) Immunogenic Proteins and their Epitopes: Implications for Vaccine Preparation
Recent Patents on Anti-Infective Drug Discovery Biomarker Approach Towards Rheumatoid Arthritis Treatment
Current Rheumatology Reviews Opioid Receptors and Their Ligands in the Musculoskeletal System and Relevance for Pain Control
Current Pharmaceutical Design Development and Uses for Monoclonal Antibodies to Chemoattractant Receptors
Current Immunology Reviews (Discontinued) Leukocyte Adhesion: A Suitable Target for Anti-Inflammatory Drugs
Current Pharmaceutical Design Chemokines as Potential Therapeutic Targets in Atherosclerosis
Current Drug Targets Epithelial-Mesenchymal Transition as a Therapeutic Target for Prevention of Ocular Tissue Fibrosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Monoclonal Antibodies in Allergy; Updated Applications and Promising Trials
Recent Patents on Inflammation & Allergy Drug Discovery Cardiovascular Disease: What's All the AGE/RAGE About?
Cardiovascular & Hematological Disorders-Drug Targets Orchestrating HIV Neutralization by Secondary Immune Response- Mediated Induction of RF Antibodies
Current Immunology Reviews (Discontinued) Mechanisms of Altered Cell Immunity and Cytotoxicity in COPD
Current Drug Targets Macrophage Inflammatory Protein 1 and CCR5 as Attractive Therapeutic Targets for HIV Infection
Recent Patents on Anti-Infective Drug Discovery Adrenal Insufficiency Caused by Locally Applied Glucocorticoids-Myth or Fact?
Current Medicinal Chemistry Monocytes and Macrophages as Cellular Targets in Liver Fibrosis
Inflammation & Allergy - Drug Targets (Discontinued) Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases
Current Drug Safety